Trial Profile
Dose Escalating, Phase 1 study evaluating efficacy and safety of Selinexor (Kpt-330) in Patients (Pts) with Relapsed / Refractory Acute Myeloid Leukemia
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Dec 2015
Price :
$35
*
At a glance
- Drugs Selinexor (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 01 Dec 2015 New trial record
- 15 Jun 2014 Interim results presented at the 19th Congress of the European Haematology Association